Recent News

554 News Items found
Sloan Kettering Institute Director Thomas J. Kelly
Thomas Kelly Honored
Sloan Kettering Institute Director Thomas J. Kelly is the co-recipient of the 2010 Louisa Gross Horwitz Prize from Columbia University.
Bottles filled with liquid
Growing Science: A Decade Devoted to Advancing Cancer Research at the Sloan Kettering Institute
A decade ago, the Sloan Kettering Institute embarked on an effort to broaden and streamline its research activities.
Alexander Rudensky
Harmful Immune Reactions Might One Day Be Curbed with Cell-Based Therapy
A team of researchers led by Memorial Sloan Kettering immunologist Alexander Rudensky has gained new understanding about regulatory T cells -- a subtype of immune cells that suppresses the immune system's reactivity.
Memorial Sloan Kettering Researchers Are 2010 Rock Stars of Science
Three Memorial Sloan Kettering Cancer Center investigators -- including the Center's new President, Craig B. Thompson -- have been featured with singer-songwriter Debbie Harry to lead the Geoffrey Beene Gives Back® 2010 Rock Stars of Science™ campaign in <i>GQ</i> magazine's December "Men of the Year" issue.
Hedvig Hricak (left) and David Scheinberg are members of the new Nanotechnology Center's executive committee, which Dr. Scheinberg chairs.
New Nanotechnology Center Combines Cutting-Edge Science with Memorial Sloan Kettering's Expertise in Patient Care
To take advantage of the growing field of nanotechnology, Memorial Sloan Kettering has established a Nanotechnology Center.
Zvi Fuks
Zvi Fuks Elected to the Institute of Medicine
Zvi Fuks has been elected a member of the Institute of Medicine, one of the highest honors in the fields of health and medicine.
Media Advisory
Kenneth Offit
Genetic Variants May Affect the Risk of Breast Cancer in Women with BRCA2 Mutations
An international study led by researchers at Memorial Sloan Kettering Cancer Center has identified genetic variants in women with <i>BRCA2</i> mutations that may increase or decrease their risk of developing breast cancer.
Samuel Danishefsky
Memorial Sloan Kettering Enters Agreement to Develop New Cancer Drug
As part of a commitment to seek new and better treatments for cancer patients, Memorial Sloan Kettering Cancer Center and Bristol-Myers Squibb are collaborating to bring a potential new cancer drug called iso-fludelone, or KOS-1803, into clinical trials.
(From left) The first four authors of the June 24 Cancer Cell study, Barry Taylor, Anuradha Gopalan, Haley Hieronymous, and Nikolaus Schultz.
Sifting Through the Prostate Cancer Genome
A team of Memorial Sloan Kettering clinicians and computational biologists have compiled the largest catalog to date of genetic alterations that occur in prostate cancer.
Study Answers Important Question about Using Carbon Nanotubes in Medicine
A multicenter study led by Memorial Sloan Kettering researchers has answered an important question about the safety of using carbon nanotubes in medicine.